About this article
FODZYME by Kiwi Biosciences is an enzyme-based supplement available at Nutriessential. Our editorial team provides evidence-based information on dietary supplements. The team did a literature review to find out whether this supplement has evidence in scientific literature or not.
How we started with this research and what we found?
We researched studies on PubMed and Google Scholar using keywords: Fodzyme by kiwi Biosciences, Kiwi Biosciences Fodzyme, Kiwi Biosciences digestive enzyme supplement. We found 2 human studies. One was published in February 2026 while the second one is still continuing.
Nutriessential found the first evidence (First published human evidence we identified)
About this study
-
This is a single-arm, open-label pre-post intervention cohort study.
-
The study intends to capture “real-world” outcomes in the 9 months duration from January 23, 2024, to September 27, 2024.
-
The study participants purchased FODMAP-targeting enzymes online, manufactured by Kiwi Biosciences.
-
Participants completed anonymous online surveys with details on demographics and symptom severity at baseline and 4-week follow-up.
About the survey:
The online survey consisted of the:
-
IBS-Subject’s Global Assessment (investigate symptoms in the IBS population.)
-
Visual analog scale for IBS
-
Food Avoidance subscale of IBS quality of life (specifically assesses changes in vigilance and frustration around food, which are primary concerns with restrictive, therapeutic diets)
-
Demographic data included age, sex, body mass index, IBS status, and subtype.
-
The question asked about IBS: “Have you ever been diagnosed with Irritable Bowel Syndrome (IBS)?” Those who responded “Yes, I received a formal diagnosis from a clinician” were categorized as those with a formal diagnosis, and those who responded “No, but I strongly suspect I have it” were categorized as those who highly suspected they had IBS.
About the supplement
This study mentioned some details on FODZYME by Kiwi Biosciences. It is a proprietary FODMAP-targeting digestive enzyme blend of 3 active enzymes: fructan hydrolase, lactase, and alpha-galactosidase. The efficacy has been recorded in vitro in reducing gas and acid production in a simulated human intestine. This digestive enzyme blend was administered directly to food. The main reason is to increase homogenization between FODMAPs and the enzymes, which will further maximise FODMAP hydrolysis. This predigestion of FODMAP content before moving to the colon may avoid FODMAP fermentation by the colonic bacteria.
About the outcomes
-
This is the first human study that provided data regarding the use of a fructan-digesting agent (fructan hydrolase) in reducing the IBS burden.
-
Out of 118 participants analysed, 78% of patients reported more than a 30% improvement in bloating.
-
The authors mentioned “This study demonstrated improvement in symptom relief in all domains except nausea/vomiting, which is potentially explained by a more central or gastric source of these symptoms, rather than a distention-mediated process.”
-
This study also reported perceived secondary benefits of this supplement in the form of improvement to quality of life and mental wellness.
Limitations of this study:
-
The risk of strong bias toward perceived efficacy.
-
The studies are reliant on patient reporting as well as characterization of their own diagnosis.
-
Not all patients may fit Rome criteria assessment of IBS.
-
Findings may not be generalizable.
-
the study is the 4-week period of time between receiving the introductory survey and the trial conclusion survey.
-
The demographics are tilted more toward older women and IBS-D than population-level rates.
Final words from authors: “Our strong positive results across symptom domains suggest potential value for this therapeutic approach, although additional controlled and long-term studies are needed to further evaluate the efficacy of these enzymatic supplements.”
Nutriessential found second evidence
A randomized, double-blind, placebo-controlled crossover trial of FODZYME is registered with clinical study ID NCT07591584
Type of study: Randomized, double-blind, placebo-controlled with estimated completion date October 26, 2026
This study is designed to assess the impact of regular use of a consumer-grade FODMAP-targeting digestive enzyme blend (FODZYME®) on gastrointestinal symptoms in adults with self-reported bloating. This blend offers a more flexible approach by targeting and breaking down FODMAPs, such as fructan, GOS, and lactose, before they ferment in the colon.
Study participants are instructed to take it with each meal, snack, or substantial beverage and apply it directly to the food.
In the study, some instructions are relatively clear:
-
Minor and temporary gastrointestinal side effects, such as GI upset, increased gas, or mild changes in bowel habits, may occur.
-
To mitigate the risk of allergic reaction, participants with a history of previous reactions to digestive enzyme supplements are excluded from the study.
-
The product is a consumer-grade supplement being evaluated in a research study and is not intended to diagnose, prevent, cure, or mitigate specific medical diseases, nor is the research intended to support FDA-regulated drug applications.
This clearly shows that we are expecting results of FODZYME by Kiwi Biosciences in October this year.
Note: The trial has an estimated completion date of October 26, 2026. Results availability and publication timing have not been confirmed.
Conclusion
FODZYME is not a supplement without research.
It is a research-supported enzyme product with promising but still developing clinical evidence not every benefit associated with its use has been conclusively established.
In future, as we get emerging information on this supplement, we will keep our readers updated. It is our responsibility to provide evidence-based information to our readers who believe in us because we are committed to providing the latest batch of science-based supplements.
Study links
A Study Evaluating the Impact of Regular FODMAP-targeting Digestive Enzyme Blend Use on Gastrointestinal Symptoms in Individuals With Self-Reported Bloating | Clinical Research Trial Listing (Source)
FODMAP-Targeting Digestive Enzyme Blend for Management of Gastrointestinal Symptoms: A “Real-World” Pre-Post Intervention Cohort Study - PMC. (Source)
